Carlo Sessa

A leading biotechnology company in Shanghai

Shanghai United Cell Biotechnology, established in 1995, has grown into a prominent biotechnology enterprise within China’s pharmaceutical sector. Operating from the Shanghai Free Trade Zone’s Jinqiao Biotechnology Industrial Park, the company combines advanced research capabilities with state-of-the-art manufacturing facilities.

Advanced facilities and production capabilities

The company’s facility encompasses 44,000 square meters of total space, housing both cosmetic lab operations and pharmaceutical manufacturing units. The production infrastructure includes specialized areas for genetic engineering, vaccine development, and various pharmaceutical formulations.

Manufacturing capacity

• 15 million freeze-dried injections annually
• 13 million cartridge vial injections
• 9 million capsules
• 5.6 million granule bags

Research and development focus

With over 10% of sales revenue directed towards R&D, Shanghai United Cell Biotechnology maintains active research platforms in multiple therapeutic areas. The company’s work spans across:

• Endocrinology
• Orthopedics
• Ophthalmology
• Anti-infection treatments

Product portfolio and expertise

Operating under strict GMP compliance, the company produces several key products including teriparatide injections, cholera vaccines, and human growth hormone preparations. The manufacturing process utilizes both prokaryotic and eukaryotic expression systems.

Strategic location and market access

Located at 1150 Gui Qiao Lu in Shanghai’s Free Trade Zone, the facility benefits from the region’s established biotechnology infrastructure and proximity to major transportation networks. This position supports efficient distribution across Asian markets while maintaining compliance with international standards.